Print

AstraZeneca PLC (AZN) Launches New Digital Resources for ARIMIDEX® (anastrozole) Tablets to Help Educate Patients About ARIMIDEX Direct  
11/12/2012 10:10:58 AM

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today launched new digital resources to educate patients on how to enroll in ARIMIDEX Direct. Resources include a “how to” video outlining the enrollment process for ARIMIDEX Direct and a digital badge that can be shared via social media platforms and symbolizes support for the program. Breast cancer treatments can impact patients financially. In fact, research has found that the estimated lifetime costs of medical care for breast cancer patients in the United States can be up to $100,000.1 However, there are programs like AstraZeneca’s ARIMIDEX Direct, which can help reduce financial strain for patients taking ARIMIDEX. ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer. Prescription ARIMIDEX is only for postmenopausal women. ARIMIDEX should not be taken if you are pregnant because it may harm your unborn child. Do not take ARIMIDEX if you are allergic to any of its ingredients. Additional Important Safety Information provided below.
//-->